Takeda Pharmaceutical Co. $TAK Stake Raised by Capital Research Global Investors

Capital Research Global Investors increased its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 0.6% in the 4th quarter, Holdings Channel reports. The fund owned 13,486,772 shares of the company’s stock after purchasing an additional 82,643 shares during the period. Capital Research Global Investors’ holdings in Takeda Pharmaceutical were worth $210,259,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Private Trust Co. NA lifted its stake in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after acquiring an additional 1,292 shares in the last quarter. Harbour Investments Inc. lifted its stake in Takeda Pharmaceutical by 300.3% in the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock worth $72,000 after acquiring an additional 3,460 shares in the last quarter. Advisory Services Network LLC purchased a new stake in Takeda Pharmaceutical in the 3rd quarter worth about $74,000. Finally, Larson Financial Group LLC lifted its stake in Takeda Pharmaceutical by 43.7% in the 3rd quarter. Larson Financial Group LLC now owns 7,823 shares of the company’s stock worth $115,000 after acquiring an additional 2,379 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $15.78 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.27 and a quick ratio of 0.70. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The stock’s 50-day moving average is $16.92 and its two-hundred day moving average is $16.67. The firm has a market cap of $50.20 billion, a P/E ratio of 40.45 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 11.07% and a net margin of 4.31%.The company had revenue of $6.90 billion for the quarter. Analysts predict that Takeda Pharmaceutical Co. will post 1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Wall Street Zen lowered Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.